Supernus Pharmaceuticals Q4 revenue rises 21% on product sales

Supernus Pharmaceuticals

24/02/2026 21:35

Overview

Biopharmaceutical firm reported Q4 2025 revenue up 21% yr/yr to $211.6 mln

Company's growth driven by Qelbree and GOCOVRI sales increase

Outlook

Supernus forecasts 2026 total revenues between $840 mln and $870 mln

Company expects 2026 adjusted operating earnings of $140 mln to $170 mln

Result Drivers

ONAPGO LAUNCH - ONAPGO sales reached $8.9 million in Q4 2025 following its U.S. launch in April 2025

ZURZUVAE COLLABORATION - Collaboration revenue from ZURZUVAE rose significantly, reflecting increased sales by Biogen

Company press release: ID:nGNXbMyD6d

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$158.10 mln
Q4 Adjusted Revenue
$196.40 mln
Q4 EPS
-$0.07
Q4 Operating Earnings
-$3.94 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $61.50, about 21.3% above its February 23 closing price of $50.69

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)